We consider that further clinical studies are needed to help us to understand the role of CFTR modulators and timing of treatment initiation in preventing EPI and malnutrition in children with CF and thus in improving the quality of life and possible the survival rate. The gene discussed is CFTR; the disease is nutritional deficiency disease.